Role of pyridoxine in GABA synthesis and degradation in the hippocampus.
Level 5 - mechanism / opinion, no new human data
Preclinical animal experiment with no human data.
PubMed 31759410 · doi:10.1016/j.tice.2019.09.005
What was done
Mice received intraperitoneal injections of either physiological saline or 350 mg/kg pyridoxine twice daily for 21 days and were euthanized 2 hours after the final dose. Hippocampal tissue was evaluated via immunohistochemistry and Western blot for immunoreactivity and protein levels of GABA-synthesizing and degrading enzymes: glutamic acid decarboxylase 67 (GAD67), GABA transaminase (GABA-T), and succinic semialdehyde dehydrogenase (SSADH).
What was found
No numerical values or effect sizes were reported in the abstract. Pyridoxine treatment significantly increased GAD67 immunoreactivity overall and significantly decreased GABA-T immunoreactivity in the hippocampal CA1 region and dentate gyrus, while significantly increasing GABA-T immunoreactivity in the stratum lacunosum-moleculare of the CA1 region. SSADH immunoreactivity showed no significant differences between groups across any hippocampal regions. Western blot analysis showed significant increases in both GAD67 and GABA-T total protein levels in the pyridoxine-treated group compared to vehicle controls.
Why it matters
The findings demonstrate that subchronic high-dose pyridoxine modulates the expression and regional distribution of key enzymes involved in hippocampal GABA turnover in rodents.
Limits
This is an animal study using high-dose intraperitoneal administration, limiting translation to human physiology and dietary intake. The abstract omits sample size (n), quantitative values, variance, and exact significance levels. Direct GABA concentrations, electrophysiological measures, and behavioral outcomes were not assessed.
Cited by
- supports Vitamin B6 is a required cofactor for converting glutamate into the inhibitory neurotransmitter GABA.